Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine

[1]  Sabine Van Huffel,et al.  Multiparametric Non-Negative Matrix Factorization for Longitudinal Variations Detection in White-Matter Fiber Bundles , 2017, IEEE Journal of Biomedical and Health Informatics.

[2]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[3]  J. Dudley,et al.  Machine-Learning Algorithms to Automate Morphological and Functional Assessments in 2D Echocardiography. , 2016, Journal of the American College of Cardiology.

[4]  Paul A. Harris,et al.  PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability , 2016, J. Am. Medical Informatics Assoc..

[5]  Joseph Loscalzo,et al.  Precision medicine in cardiology , 2016, Nature Reviews Cardiology.

[6]  He Zhang,et al.  Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension , 2016, Nature Genetics.

[7]  S. Ekins.  The Next Era: Deep Learning in Pharmaceutical Research , 2016, Pharmaceutical Research.

[8]  S. Benvenuti,et al.  Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer , 2016, Journal of Translational Medicine.

[9]  N. Sarrafzadegan,et al.  The role of serum levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome , 2016, Molecular and Cellular Biochemistry.

[10]  K. Kerr,et al.  Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Thomas Quertermous,et al.  Genetics and Genomics of Coronary Artery Disease , 2016, Current Cardiology Reports.

[12]  Jing Cheng,et al.  Association of Soluble Fibrinogen-like Protein 2 with the Severity of Coronary Artery Disease. , 2016, Internal medicine.

[13]  T. Yen,et al.  Clues toward precision medicine in oral squamous cell carcinoma: utility of next-generation sequencing for the prognostic stratification of high-risk patients harboring neck lymph node extracapsular extension , 2016, Oncotarget.

[14]  François Laviolette,et al.  Predictive computational phenotyping and biomarker discovery using reference-free genome comparisons , 2016, BMC Genomics.

[15]  Chittibabu Guda,et al.  Classification of breast cancer patients using somatic mutation profiles and machine learning approaches , 2016, BMC Systems Biology.

[16]  J. Ramírez,et al.  Ensembles of Deep Learning Architectures for the Early Diagnosis of the Alzheimer's Disease , 2016, Int. J. Neural Syst..

[17]  J. Ruidavets,et al.  Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study , 2016, BMC Medicine.

[18]  Tom Michoel,et al.  Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases , 2016, Science.

[19]  Jimeng Sun,et al.  Using recurrent neural network models for early detection of heart failure onset , 2016, J. Am. Medical Informatics Assoc..

[20]  Zhaohui Liang,et al.  DL-ADR: a novel deep learning model for classifying genomic variants into adverse drug reactions , 2016, BMC Medical Genomics.

[21]  Z. Meng,et al.  Plasma MicroRNA-126-5p is Associated with the Complexity and Severity of Coronary Artery Disease in Patients with Stable Angina Pectoris , 2016, Cellular Physiology and Biochemistry.

[22]  Lisa Kennedy Sheldon.  Oncology Nurses and the Cancer Moonshot 2020. , 2016, Clinical journal of oncology nursing.

[23]  Lawrence H. Kushi,et al.  Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals. , 2016, JAMA cardiology.

[24]  Kevin J. Emmett,et al.  Topological Data Analysis Generates High-Resolution, Genome-wide Maps of Human Recombination. , 2016, Cell systems.

[25]  B. Goldstein,et al.  Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges , 2016, European heart journal.

[26]  Stephanie N. Thompson,et al.  The Impact of Biochemical Markers on Major Adverse Cardiovascular Events and Contralateral Carotid Artery Stenosis Progression Following Carotid Interventions. , 2016, Annals of vascular surgery.

[27]  Hui Li,et al.  Digital mammographic tumor classification using transfer learning from deep convolutional neural networks , 2016, Journal of medical imaging.

[28]  Tero Aittokallio,et al.  Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization , 2016, Bioinform..

[29]  Li Li,et al.  Comparative analyses of population-scale phenomic data in electronic medical records reveal race-specific disease networks , 2016, Bioinform..

[30]  Sergey Plis,et al.  Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. , 2016, Molecular pharmaceutics.

[31]  M. Pirmohamed,et al.  Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden , 2016, The Pharmacogenomics Journal.

[32]  J. Rumsfeld,et al.  Big data analytics to improve cardiovascular care: promise and challenges , 2016, Nature Reviews Cardiology.

[33]  J. Dudley,et al.  Cognitive Machine-Learning Algorithm for Cardiac Imaging: A Pilot Study for Differentiating Constrictive Pericarditis From Restrictive Cardiomyopathy. , 2016, Circulation. Cardiovascular imaging.

[34]  Li Li,et al.  Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records , 2016, Scientific Reports.

[35]  Puneet Kumar,et al.  Pleiotropic effects of statins: new therapeutic targets in drug design , 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

[36]  H. Schunkert,et al.  The impact of genome‐wide association studies on the pathophysiology and therapy of cardiovascular disease , 2016, EMBO molecular medicine.

[37]  Sanjiv J. Shah,et al.  Developing New Treatments for Heart Failure: Focus on the Heart , 2016, Circulation. Heart failure.

[38]  Eric Boerwinkle,et al.  Genetic loci associated with ideal cardiovascular health: A meta-analysis of genome-wide association studies. , 2016, American heart journal.

[39]  Khader Shameer,et al.  In silico methods for drug repurposing and pharmacology , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.

[40]  Phillip L. Williams,et al.  The US Cancer Moonshot initiative. , 2016, The Lancet. Oncology.

[41]  Michael J. Keiser,et al.  Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. , 2016, The lancet. Psychiatry.

[42]  R. Hegele,et al.  Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? , 2016, Current Atherosclerosis Reports.

[43]  Tom Michoel,et al.  Cross-Tissue Regulatory Gene Networks in Coronary Artery Disease , 2016, Cell systems.

[44]  P. Barter,et al.  Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead—Pro , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[45]  Ravikiran Korabathina,et al.  Heart Failure Update: Diagnosis and Classification. , 2016, FP essentials.

[46]  Marcus A. Badgeley,et al.  EHDViz: clinical dashboard development using open-source technologies , 2016, BMJ Open.

[47]  Kipp W. Johnson,et al.  Medical student preparedness for an era of personalized medicine: findings from one US medical school. , 2016, Personalized medicine.

[48]  R. Green,et al.  Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). , 2016, Circulation.

[49]  M. Dougados,et al.  Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis , 2016, PloS one.

[50]  Joseph Loscalzo,et al.  Opportunities for the Cardiovascular Community in the Precision Medicine Initiative , 2016, Circulation.

[51]  Andrew Janowczyk,et al.  Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases , 2016, Journal of pathology informatics.

[52]  G. Schneider,et al.  Deep Learning in Drug Discovery , 2016, Molecular informatics.

[53]  Sherry-Ann Brown,et al.  Systems biology approaches to adverse drug effects: the example of cardio-oncology , 2015, Nature Reviews Clinical Oncology.

[54]  V. Sukhatme,et al.  Drug repurposing in oncology—patient and health systems opportunities , 2015, Nature Reviews Clinical Oncology.

[55]  H. D. den Ruijter,et al.  Biomarkers of Coronary Artery Disease Differ Between Asians and Caucasians in the General Population. , 2015, Global heart.

[56]  Pak Chung Sham,et al.  GWASdb v2: an update database for human genetic variants identified by genome-wide association studies , 2015, Nucleic Acids Res..

[57]  W. Galanter,et al.  Cost-Effectiveness Of A Novel Pharmacist Guided Warfarin Pharmacogenetic Service. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[58]  Benjamin S. Glicksberg,et al.  Identification of type 2 diabetes subgroups through topological analysis of patient similarity , 2015, Science Translational Medicine.

[59]  Adam R Ferguson,et al.  Topological data analysis for discovery in preclinical spinal cord injury and traumatic brain injury , 2015, Nature Communications.

[60]  Olivier Bodenreider,et al.  The digital revolution in phenotyping , 2015, Briefings Bioinform..

[61]  S. Jaffe.  Planning for US Precision Medicine Initiative underway , 2015, The Lancet.

[62]  G. Pitt.  Cardiovascular precision medicine: hope or hype? , 2015, European heart journal.

[63]  Euan A Ashley,et al.  The precision medicine initiative: a new national effort. , 2015, JAMA.

[64]  C. Newton-Cheh,et al.  Genome-wide association studies of late-onset cardiovascular disease. , 2015, Journal of molecular and cellular cardiology.

[65]  Anne Corbett,et al.  Drug repositioning in Alzheimer's disease. , 2015, Frontiers in bioscience.

[66]  D. DeMets,et al.  Cardiovascular drug development: is it dead or just hibernating? , 2015, Journal of the American College of Cardiology.

[67]  G. Felker,et al.  Reply: applying cluster analysis to data of previously published chronic heart failure trials: systems biology and clinical phenotypes of heart failure syndrome. , 2015, Journal of the American College of Cardiology.

[68]  J. Madias.  Applying cluster analysis to data of previously published chronic heart failure trials. , 2015, Journal of the American College of Cardiology.

[69]  G. Louridas,et al.  Systems biology and clinical phenotypes of heart failure syndrome. , 2015, Journal of the American College of Cardiology.

[70]  Joel T. Dudley,et al.  Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. , 2015, Journal of the American College of Cardiology.

[71]  Borislav Dimitrov,et al.  Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data , 2015, The Lancet.

[72]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[73]  L. Newby,et al.  Back to the future: improving the use of guidelines-recommended coronary disease secondary prevention at the dawn of the precision medicine era. , 2015, Circulation.

[74]  Andrew E Moran,et al.  Cost-effectiveness of hypertension therapy according to 2014 guidelines. , 2015, The New England journal of medicine.

[75]  Nabil Zary,et al.  Visual analytics in healthcare education: exploring novel ways to analyze and represent big data in undergraduate medical education , 2014, PeerJ.

[76]  Casey S. Greene,et al.  Unsupervised Feature Construction and Knowledge Extraction from Genome-Wide Assays of Breast Cancer with Denoising Autoencoders , 2014, Pacific Symposium on Biocomputing.

[77]  Li Li,et al.  An Integrative Pipeline for Multi-Modal Discovery of Disease Relationships , 2014, Pacific Symposium on Biocomputing.

[78]  Krishna R. Kalari,et al.  The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data , 2014, Nucleic acids research.

[79]  T. Thenappan,et al.  The heterogeneity of heart failure: will enhanced phenotyping be necessary for future clinical trial success? , 2014, Journal of the American College of Cardiology.

[80]  I. Kullo,et al.  Whole Exome Sequencing Implicates an INO80D Mutation in a Syndrome of Aortic Hypoplasia, Premature Atherosclerosis, and Arterial Stiffness , 2014, Circulation. Cardiovascular genetics.

[81]  Damian Smedley,et al.  Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome , 2014, Science Translational Medicine.

[82]  S. Oparil,et al.  Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010 , 2014, PloS one.

[83]  W. März,et al.  Evolving biomarkers improve prediction of long‐term mortality in patients with stable coronary artery disease: the BIO‐VILCAD score , 2014, Journal of internal medicine.

[84]  C. Chute,et al.  The ATXN2-SH2B3 locus is associated with peripheral arterial disease: an electronic medical record-based genome-wide association study , 2014, Front. Genet..

[85]  J. Williamson,et al.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) , 2014, Clinical trials.

[86]  Michael T. Zimmermann,et al.  Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics , 2014, Bioconjugate chemistry.

[87]  C. Creighton,et al.  DRUG-REPOSITIONING SCREENING IDENTIFIED PIPERLONGUMINE AS A DIRECT STAT3 INHIBITOR WITH POTENT ACTIVITY AGAINST BREAST CANCER , 2014, Oncogene.

[88]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[89]  M Pirmohamed,et al.  Cost‐Effectiveness of Pharmacogenetics‐Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation , 2014, Clinical pharmacology and therapeutics.

[90]  J. You.  Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis , 2014, Pharmacogenetics and genomics.

[91]  A. Butte,et al.  Network Medicine in Disease Analysis and Therapeutics , 2013, Clinical pharmacology and therapy.

[92]  M. Cleman,et al.  Colchicine and the heart: pushing the envelope. , 2013, Journal of the American College of Cardiology.

[93]  Christopher G. Chute,et al.  A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects , 2013, Human Genetics.

[94]  W. Cheung,et al.  Predicting the risk of cardiovascular comorbidities in adult cancer survivors. , 2013, Current oncology.

[95]  Melissa A. Basford,et al.  The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future , 2013, Genetics in Medicine.

[96]  P. Serruys,et al.  Coronary stents: historical development, current status and future directions. , 2013, British medical bulletin.

[97]  Natalia Novac,et al.  Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.

[98]  J. Medina-Franco,et al.  Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.

[99]  M. Vaduganathan,et al.  The disconnect between phase II and phase III trials of drugs for heart failure , 2013, Nature Reviews Cardiology.

[100]  Noam Shomron,et al.  Pharmaco-miR: linking microRNAs and drug effects , 2013, Briefings Bioinform..

[101]  R. Burt,et al.  Social network analysis: foundations and frontiers on advantage. , 2013, Annual review of psychology.

[102]  C. Antoniades,et al.  Translating the effects of statins: From redox regulation to suppression of vascular wall inflammation , 2012, Thrombosis and Haemostasis.

[103]  Jin-jian Lu,et al.  Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.

[104]  I. Kohane,et al.  Escaping the EHR trap--the future of health IT. , 2012, The New England journal of medicine.

[105]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[106]  Y. Birnbaum,et al.  Pleiotropic Effects of Statins: The Role of Eicosanoid Production , 2012, Current Atherosclerosis Reports.

[107]  P. Visscher,et al.  Five years of GWAS discovery. , 2012, American journal of human genetics.

[108]  K. Chalkidou,et al.  Pharmacogenetics and cost-effectiveness analysis: a two-way street. , 2011, Drug discovery today.

[109]  Ramanathan Sowdhamini,et al.  3dswap-pred: prediction of 3D domain swapping from protein sequence using Random Forest approach. , 2011, Protein and peptide letters.

[110]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[111]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[112]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[113]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[114]  S. Omholt,et al.  Phenomics: the next challenge , 2010, Nature Reviews Genetics.

[115]  Christos G Mihos,et al.  The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease: A Comprehensive Review , 2010, Cardiology in review.

[116]  F. Collins,et al.  Genomic medicine--an updated primer. , 2010, The New England journal of medicine.

[117]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[118]  Ponnuthurai N. Suganthan,et al.  Bioinformatics and Biology Insights , 2022 .

[119]  Rohina Joshi,et al.  An Electronic Clinical Decision Support Tool to Assist Primary Care Providers in Cardiovascular Disease Risk Management: Development and Mixed Methods Evaluation , 2009, Journal of medical Internet research.

[120]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[121]  R. Hegele,et al.  The failure of torcetrapib: what have we learned? , 2008, British journal of pharmacology.

[122]  P Michael Ho,et al.  Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. , 2008, American heart journal.

[123]  T. Nakagawa,et al.  Pathogenesis of essential hypertension: historical paradigms and modern insights , 2008, Journal of hypertension.

[124]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[125]  R. Machado,et al.  Sildenafil in the treatment of pulmonary hypertension , 2006, Vascular health and risk management.

[126]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[127]  M. Millan.  Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, Pharmacology & therapeutics.

[128]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[129]  Z. Oltvai,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[130]  J. Zurlo,et al.  Trimethoprim-sulfamethoxazole revisited. , 2003, Archives of internal medicine.

[131]  B. Gersh,et al.  Modern management of acute myocardial infarction. , 2003, Current problems in cardiology.

[132]  Francis S. Collins,et al.  Genomic medicine--a primer. , 2002, The New England journal of medicine.

[133]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[134]  David F. Horrobin,et al.  Realism in drug discovery—could Cassandra be right? , 2001, Nature Biotechnology.

[135]  C. Adami,et al.  Evolution of Biological Complexity , 2000, Proc. Natl. Acad. Sci. USA.

[136]  A J Sefton,et al.  Healthcare and the information age: implications for medical education , 1998, The Medical journal of Australia.

[137]  W. Zapol,et al.  Cyclic-GMP-Binding, Cyclic-GMP-Specific Phosphodiesterase (PDE5) Gene Expression Is Regulated during Rat Pulmonary Development , 1998, Pediatric Research.

[138]  C. Charles,et al.  Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). , 1997, Social science & medicine.

[139]  M. Ondetti,et al.  History of the Design of Captopril and Related Inhibitors of Angiotensin Converting Enzyme , 1991, Hypertension.

[140]  K. Swedberg,et al.  PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.

[141]  E. Braunwald,et al.  The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. , 1966, Annals of internal medicine.

[142]  Copeman Pw,et al.  LUNG CANCER AND SMOKING. , 1964, Lancet.

[143]  Gustavo Carneiro,et al.  Combining deep learning and level set for the automated segmentation of the left ventricle of the heart from cardiac cine magnetic resonance , 2017, Medical Image Anal..

[144]  A. Koong,et al.  A Multimodal Data Analysis Approach for Targeted Drug Discovery Involving Topological Data Analysis (TDA). , 2016, Advances in experimental medicine and biology.

[145]  Khader Shameer,et al.  Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. , 2015, Current topics in medicinal chemistry.

[146]  Emily C. O'Brien,et al.  Clinical Implications of Chronic Heart Failure Phenotypes De fi ned by Cluster Analysis , 2015 .

[147]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[148]  C. Kulikowski,et al.  Viewpoint Paper: Bioinformatics and Medical Informatics: Collaborations on the Road to Genomic Medicine? , 2003, J. Am. Medical Informatics Assoc..

[149]  D. Hand,et al.  Unsupervised Profiling Methods for Fraud Detection , 2002 .

[150]  D R Allington,et al.  Quinupristin/dalfopristin: a therapeutic review. , 2001, Clinical therapeutics.

[151]  ICHAEL,et al.  THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE , 2000 .

[152]  Yanjun Qi,et al.  Advance Access Publication Date: Day Month Year Manuscript Category Deepchrome: Deep-learning for Predicting Gene Expression from Histone Modifications , 2022 .

[153]  Andros Tofield.  The emergence of cardiovascular imaging as a subspecialty and individualized treatment of coronary artery disease : two related trends Based on experience of setting up several multimodality centres of cardiovascular imaging , 2022 .